Figure 3 from In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

Nf2 loss results in RasG12D-induced oncogenesis and cooperates with Trp53 loss to accelerate ICC formation. A, Kaplan–Meier curve demonstrating the relative survival proportions of mice with KRASG12D&...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Nicholas T. Younger (14956251) (author)
Autres auteurs:	Mollie L. Wilson (14956254) (author), Anabel Martinez Lyons (14956257) (author), Edward J. Jarman (9773166) (author), Alison M. Meynert (14956260) (author), Graeme R. Grimes (14160170) (author), Konstantinos Gournopanos (14956263) (author), Scott H. Waddell (14956266) (author), Peter A. Tennant (14956269) (author), David H. Wilson (14956272) (author), Rachel V. Guest (14956275) (author), Stephen J. Wigmore (14915943) (author), Juan Carlos Acosta (14956278) (author), Timothy J. Kendall (14956281) (author), Martin S. Taylor (14956284) (author), Duncan Sproul (13971883) (author), Pleasantine Mill (256953) (author), Luke Boulter (14956287) (author)
Publié:	2025
Sujets:	Cancer Cancer Biology Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Signaling Computational Methods Sequence analysis Drug Targets Gastrointestinal Cancers Liver cancer Gene Technologies Comparative genomics Oncogenes & Tumor Suppressors Kras Preclinical Models Animal models of cancer
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma

Documents similaires